The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | LOTIS-5: loncastuximab tesirine + rituximab for elderly patients with R/R DLBCL
Elderly patients with diffuse large B-cell lymphoma (DLBCL) who relapse after frontline chemotherapy and are ineligible for autologous stem cell transplantation (autoSCT) have limited treatment options. Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the LOTIS-5 trial (NCT04384484), a randomized Phase III trial comparing the combination of loncastuximab tesirine and rituximab (Lonca-R) to chemoimmunotherapy with rituximab, gemcitabine and oxaliplatin (R-GemOx) in this patient population. Prof. Carlo-Stella shares the results from the safety run-in period, where Lonca-R did not result in any new toxicity signals, and discusses the current stage of enrolment. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role ADC Therapeutics, Celgene/Bristol Myers Squibb, Karyopharm, Novartis, Sanofi, Roche, Merck Sharp & Dohme, Scenic Biotech
Honoraria: Merck Sharp & Dohme, Janssen Oncology, AstraZeneca, Celgene, Incyte, Gilead Sciences, Roche
